Currently, the European LeukemiaNet (ELN) recommendations for AML classify translocations involving KMT2A as either intermediate-(t(9;11)(p21.3;q23.3)/KMT2A::MLLT3) or adverse-(t(v;11q23.3)/KMT2A-rearranged) genetic risk [2]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.